Flow cytometry analysis of human CD45+ cells in the bone marrow and spleen revealed a substantial reduction in human CML tumor blast following combined treatment with Chi and IM, compared to either treatment alone (Fig. 7e, f). The gene discussed is PTPRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.